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See Article, pages 293–300Russmann et al. describe spontaneous reports of drug-induced
liver injury after rivaroxaban to the Swiss pharmacovigilance
system [1]. They also found a similar signal in large spontaneous
report databases (EMA, USFDA, WHO UMC monitoring centre).
The causality of rivaroxaban in these cases is plausible, and
rivaroxaban may indeed be associated with liver injury, as most
drugs are. However caution may be warranted in the interpreta-
tion of these ﬁndings, and especially before any ﬁrm conclusions
are drawn or actions suggested.
Ten of the fourteen reported cases occurred after surgery,
mostly total knee replacement, which involves anaesthetics and
other drugs that may be hepatotoxic. Surgery itself may result in
hepatic injury through transient low output syndrome in these
often elderly patients. Most would also receive analgesics such as
NSAIDs, even if this would be unlikely because of the use of antico-
agulants, or paracetamol with or without opiates. Paracetamol
may also be hepatotoxic even at ‘‘normal’’ doses [2]. This does
not seem to have been mentioned in the case descriptions. In the
cases that occurred in patients using the anticoagulant for atrial
ﬁbrillation (AF) there is no anaesthetic or analgesic risk but AF
can cause episodes of low cardiac output that may also be injuri-
ous, andotherhepatotoxicdrugs suchas amiodarone areoftenused.
Therefore, considering the drug and the medical environment,
one is not surprised at ﬁnding cases of hepatic injury in such
patients. Causality may point to rivaroxaban as the more suspect
drug, but causality assessment, even for hepatic-speciﬁc methods
such as RUCAM [3], is only as trustworthy as the data used, and
the lack of description of anaesthetic procedures, or analgesic
or other drugs is a little worrisome [4].
Looking at other reporting databases is useful to support a sig-
nal. However, the WHO UMC database includes information from
other databases, since it simply compiles data sent by individual
countries. As such it is a secondary database, not a primary one. It
would duplicate Eudravigilance data, and the FDA data. The FDA
database itself includes cases occurring within the US, and indus-
try-reported cases from outside the US: these may also be found
in Eudravigilance, and in theWHO database. A very small number
of cases may become an epidemic. These databases show that
cases may exist, but the actual number of cases and their mean-
ing are uncertain.Journal of Hepatology 20
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duplicate reports in the different databases and give a clearer
vision of real numbers of individual reports. However, it will cer-
tainly not provide actual event rates [5].
Even if the cases were to demonstrate the existence of hepatic
injury associated with rivaroxaban, is this drug worse than the
alternatives?
There are reports of hepatic injury with warfarin and ﬂuindi-
one [6]. Ximelagatran was stopped because of hepatic injury dur-
ing clinical trials [7]. There is as yet little or no post-marketing
information on the other NOACs. A meta-analysis of clinical trials
concerning NOACs and vitamin-K antagonists (VKA) found no dif-
ference between NOACs and VKA for hepatic problems [8]. Wat-
kins et al. did not ﬁnd an increased risk of liver injury compared
to enoxaparin in another meta-analysis of clinical trials [9].
Several NOACs (rivaroxaban, apixaban, dabigatran, and oth-
ers) have been recently or will be put on the market and are being
carefully monitored for relative effectiveness and bleeding risk.
Carefully designed pharmacoepidemiological studies may also
be able to give a reasonable answer for a possible hepatotoxicity,
differential or not. If conﬁrmed, it will obviously also have to be
put in balance with the other risks of these drugs, especially of
intracranial bleeding. Unless the liver toxicity leads to transplan-
tation [2], the liver usually recovers. The same can unfortunately
not be said of the brain after stroke.
Proactive safety monitoring is certainly warranted before any
ﬁrm conclusion is drawn or regulatory action is taken.
There may be a signal, and there may even be an alert. But is it
really an alarm?Conﬂict of interest
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